ViroGates and GENSPEED achieve proof of concept for their suPARnostic® POC+ targeted at the Longevity Testing Market
Resolutions from the Extraordinary General Meeting of ViroGates A/S
ViroGates gives notice to convene an Extraordinary General Meeting on 21 May 2025
Revenue comparable to the same period last year, operating expenses reduced by 33%, and an amended agreement with Sobi
Resolutions from the Annual General Meeting of ViroGates A/S
ViroGates gives notice to convene the Annual General Meeting on 24 April 2025
Revenue declines by 12 % compared to last year as ViroGates continues the transition into the health- and longevity segment and fosters stra...
ViroGates announces an amendment to its agreement with Sobi
ViroGates issues warrants to key employees
ViroGates publishes its financial calendar for 2025
ViroGates announces financial guidance for 2025
ViroGates announces a reorganisation of its marketing and sales department and revises its guidance for the year
ViroGates’ capital raise of DKK 8.2 million and issue of 1,289,510 new shares have been registered
ViroGates announces its Interim Report for Q1-Q3 2024: Revenues are disappointing, but strategic refocusing will pave the way for future gro...
ViroGates announces an agreement with US-based suPAR Health to distribute its blood test for chronic inflammation within the United States.
ViroGates announces its half-year report for H1 2024: Revenue for the first half-year of 2024 falls behind the same period in 2023 due to lo...
ViroGates announces revised financial guidance for 2024
